Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06894004

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Very-low carbohydrate ketogenic diets can dramatically increase blood cholesterol levels, particularly in normal-weight people, for reasons that are not well understood. This study will enroll normal-weight adults, will identify "responders" who develop high cholesterol on a ketogenic diet, and will measure rates of production and removal of certain types of cholesterol-carrying particles called lipoproteins in responders. The results will clarify the mechanism by which a ketogenic diet can cause high cholesterol in certain susceptible people.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location status: Recruiting

Location contact

Max C Petersen, M.D., Ph.D.

CONTACT

[email protected]

314-362-8450

Max C Petersen, M.D., Ph.D.

PRINCIPAL_INVESTIGATOR

Nikki Plassmeyer, M.A., R.D.N., L.D.

CONTACT

[email protected]

(314) 362-0590

About this study

This study will evaluate the mechanism of ketogenic diet-induced hypercholesterolemia in susceptible normal-weight adults. The first stage of screening will identify eligible young adults who are normal-weight and at low cardiovascular risk. The second stage of screening will identify "responders" who demonstrate susceptibility to ketogenic diet-induced hypercholesterolemia by displaying an increase in LDL-cholesterol concentration after a 3-week screening ketogenic diet. Responders will be eligible to complete a randomized crossover clinical study at Washington University School of Medicine in St. Louis, MO. The randomized crossover study will involve isotope tracer studies of lipoprotein and cholesterol kinetics after two separate 4-week dietary interventions [ketogenic diet and control diet], conducted in random order with a 4-week washout period between interventions. All food will be provided to the participants as packed-out meals. Certain outcomes will use data from the screening process, comparing screen successes and screen failures to evaluate factors that could influence susceptibility to ketogenic diet-induced hypercholesterolemia.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age ≥ 18 and < 40 years
  • BMI ≥ 18.5 and < 25.0 kg/m2
  • baseline serum LDL-c < 150 mg/dL (< 3.9 mmol/L)
  • baseline serum TG < 100 mg/dL (< 1.1 mmol/L)
  • HbA1c ≤ 5.6%.

Exclusion criteria

  • personal or family history of familial hypercholesterolemia
  • current use of lipid-lowering drugs
  • currently on a ketogenic diet and unwilling to change diet
  • current tobacco use
  • hypertension
  • prediabetes or diabetes
  • elevated Lp(a) > 6.5% of ApoB-containing lipoproteins at baseline
  • oral contraceptive use
  • contraindication to heparin
  • known atherosclerotic cardiovascular disease
  • unwilling to abstain from alcohol

Treatment and study plan

Ketogenic diet

Behavioral

Participants will consume an isocaloric ketogenic diet for 4 weeks with all food provided as packed-out meals.

Control diet

Behavioral

Participants will consume an isocaloric control diet for 4 weeks with all food provided as packed-out meals.

Primary outcomes

  1. VLDL-ApoB100 production rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and VLDL-ApoB100 leucine isotopic enrichment and compartmental modeling

Secondary outcomes

  1. VLDL-ApoB100 fractional catabolic rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and VLDL-ApoB100 leucine isotopic enrichment and compartmental modeling

  2. IDL-ApoB100 production rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and IDL-ApoB100 leucine isotopic enrichment and compartmental modeling

  3. IDL-ApoB100 fractional catabolic rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and IDL-ApoB100 leucine isotopic enrichment and compartmental modeling

  4. LDL-ApoB100 production rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and LDL-ApoB100 leucine isotopic enrichment and compartmental modeling

  5. LDL-ApoB100 fractional catabolic rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and LDL-ApoB100 leucine isotopic enrichment and compartmental modeling

  6. VLDL-triglyceride production rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and VLDL glycerol isotopic enrichment and compartmental modeling

  7. VLDL-triglyceride fractional catabolic rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and VLDL glycerol isotopic enrichment and compartmental modeling

  8. Plasma lipoprotein lipase activity

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by assaying lipoprotein lipase activity in post-heparin plasma

  9. Plasma lipoprotein profile

    Time frame: At baseline, immediately after the screening ketogenic diet, immediately after the 4-week ketogenic diet intervention period, and immediately after the 4-week control diet intervention period.

    Determined by standard clinical chemistry methods and by advanced lipoprotein profiling

  10. Whole-body lipolytic rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma palmitate isotopic enrichment

  11. Relative contribution of systemic fatty acids to VLDL-triglyceride

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using plasma and VLDL-triglyceride palmitate isotopic enrichment and compartmental modeling

  12. Cholesterol synthetic rate

    Time frame: Immediately after the 4-week ketogenic diet intervention period and immediately after the 4-week control diet intervention period.

    Determined by using mass isotopomer distribution analysis of deuterium enrichment in plasma cholesterol after labeling the total body water pool with deuterium oxide

  13. Fat mass

    Time frame: Immediately after the screening ketogenic diet

    Determined by using dual-energy X-ray absorptiometry

  14. Fat-free mass

    Time frame: Immediately after the screening ketogenic diet

    Determined by using dual-energy X-ray absorptiometry

  15. Insulin sensitivity

    Time frame: Immediately after the screening ketogenic diet

    Determined by measuring fasting plasma glucose, insulin, and C-peptide

  16. Thyroid function

    Time frame: Immediately after the screening ketogenic diet

    Determined by measuring TSH, free T4, and free T3

  17. Adipokines

    Time frame: Immediately after the screening ketogenic diet

    Determined by measuring plasma leptin and adiponectin

  18. Cholesterol absorption markers

    Time frame: Immediately after the screening ketogenic diet

    Determined by measuring serum campesterol, sitosterol, and cholestanol

Study contacts

Contact information is provided by the study sponsor or research team.

Frannie Wilkinson, M.A.

CONTACT

[email protected]

(314) 362-0590

Max C Petersen, M.D., Ph.D.

CONTACT

[email protected]

314-362-8352

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Mar 25, 2025
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.